These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31641778)

  • 1. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
    Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA.
    Bakkaloglu SA; Bacchetta J; Lalayiannis AD; Leifheit-Nestler M; Stabouli S; Haarhaus M; Reusz G; Groothoff J; Schmitt CP; Evenepoel P; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2021 Feb; 36(3):413-425. PubMed ID: 33245331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
    Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
    BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
    Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H
    Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
    Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series.
    Zamoner SMS; Takase HM; Riyuzo MC; Caramori JCT; de Andrade LGM
    Int Urol Nephrol; 2024 May; 56(5):1669-1676. PubMed ID: 37964112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
    Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
    PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hyperphosphatemia: the dangers of high PTH levels.
    Bacchetta J
    Pediatr Nephrol; 2020 Mar; 35(3):493-500. PubMed ID: 31696357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
    Haffner D; Leifheit-Nestler M
    Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
    Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
    Wang AY; Lo WK; Cheung SC; Tang TK; Yau YY; Lang BH
    Nephrol Dial Transplant; 2023 Jul; 38(8):1823-1835. PubMed ID: 36869794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years
.
    Joseph C; Shah S; Geer J; Juarez-Calderon M; Srivaths PR; Swartz SJ
    Clin Nephrol; 2019 Dec; 92(6):279-286. PubMed ID: 31587754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
    Chen P; Sohn W; Narayanan A; Gisleskog PO; Melhem M
    Br J Clin Pharmacol; 2019 Jun; 85(6):1312-1325. PubMed ID: 30756425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.